Brief: Tarsus Pharmaceuticals Q3 EPS USD -0.3
04/11/2025 21:05
Nov 04 (Reuters) - Tarsus Pharmaceuticals Q3 revenue USD 118.697 million vs. IBES estimate USD 113.1 million. Q3 net income USD -12.585 million Q3 basic EPS USD -0.3
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)